MT-2 (Melanotan 2) Complete Research Guide 2026

Melanotan 2 (MT-2) is a cyclic synthetic analogue of alpha-melanocyte stimulating hormone (α-MSH), the endogenous melanocortin peptide derived from POMC cleavage. As a broad-spectrum melanocortin receptor agonist, MT-2 activates MC1R through MC4R with varying affinity, producing a diverse array of documented biological effects studied across multiple research models.

Molecular Structure and Receptor Pharmacology

MT-2 is a cyclic heptapeptide (Ac-Nle4-c[Asp5,D-Phe7,Lys10]-α-MSH4-10-NH2) incorporating several modifications improving potency and stability:

Nle4 substitution — Replacement of methionine with norleucine eliminates oxidation susceptibility, improving chemical stability.

D-Phe7 substitution — Incorporation of D-phenylalanine increases receptor binding affinity and resistance to proteolytic degradation.

Cyclization — The cyclic structure through an Asp-Lys lactam bridge constrains the peptide in a bioactive conformation, dramatically increasing potency versus linear α-MSH.

MT-2 activates all five melanocortin receptor subtypes: MC1R (expressed in melanocytes — drives eumelanin synthesis), MC3R (expressed in hypothalamus — involved in energy homeostasis), MC4R (expressed in hypothalamic paraventricular nucleus — mediates central effects through distinct pathways from PDE5 inhibitors), and MC5R (expressed in exocrine glands).

Pigmentation Research

MT-2's most documented biological effect is eumelanin synthesis in melanocytes. MC1R activation drives intracellular cAMP elevation through Gαs coupling, activating PKA and downstream MITF — the master regulator of melanocyte differentiation and melanin synthesis genes. Published research characterized dose-dependent increases in skin pigmentation across multiple skin phototypes. The pigmentation effect differs from UV-induced tanning in that it proceeds through direct MC1R activation independent of UV exposure — though research documented synergistic effects when both are combined.

Central Effects Research

MT-2's MC4R activity in the hypothalamus has made it one of the most studied compounds in sexual response research. MC4R-expressing neurons in the paraventricular nucleus project to spinal cord autonomic centers controlling vascular responses relevant to sexual function. The central mechanism is fundamentally distinct from peripheral PDE5 inhibitors, making MT-2 a research tool for characterizing central versus peripheral sexual response pathways. MC4R-knockout animal studies confirmed the receptor's requirement for MT-2's central effects.

Pharmacokinetics

MT-2 has a reported plasma half-life of approximately 30-40 minutes following subcutaneous administration. Despite this relatively short half-life, the biological effects — particularly pigmentation changes — persist significantly longer due to downstream transcriptional changes in melanocytes. Reconstituted MT-2 in bacteriostatic water is stable under refrigerated conditions within the stability window specified on batch COAs.

Safety Profile in Research

Nausea — The most consistently reported acute effect, attributed to MC3R activation in the brain stem area postrema. Dose-dependent, typically occurring within 1-2 hours of administration.

Facial flushing — Attributed to vasodilatory effects, common in published case reports.

Nevi changes — Multiple published case reports document darkening and growth of existing melanocytic nevi during MT-2 use, attributed to MC1R-driven melanocyte activation. This finding has generated ongoing research interest in melanocortin receptor activation and nevi biology.

Blood pressure effects — Transient BP changes documented in some research subjects, attributed to MC3R and MC4R cardiovascular effects.

MT-2 is a research compound. Not approved for therapeutic use. Not for human consumption. For laboratory research use only per Ares Research terms.